Author:
Zhao Yan,Duran Rafael,Chapiro Julius,Sohn Jae Ho,Sahu Sonia,Fleckenstein Florian,Smolka Susanne,Pawlik Timothy M.,Schernthaner Rüdiger,Zhao Li,Lee Howard,He Shuixiang,Lin MingDe,Geschwind Jean-François
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010;127(12):2893-917. doi:10.1002/ijc.25516.
2. Global battle against cancer won’t be won with treatment alone--effective prevention measures urgently needed to prevent cancer crisis. Central European Journal of Public Health. 2014;22(1):23, 8.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore, Md). 2005;42(5):1208-36. doi:10.1002/hep.20933.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2009;10(1):25-34. doi:10.1016/s1470-2045(08)70285-7.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine. 2008;359(4):378-90. doi:10.1056/NEJMoa0708857.